PATENTS - Criteria for patent protection - Non-obviousness - Utility - Doctrine of sound prediction
Appeal by Pharmascience from trial judgment finding the respondents’ 802 Patent was valid and that the appellant’s drug Glatect, a generic version of the respondents’ product Copaxone, would infringe the 802...To view the full article, register now.
Already a subscriber? Click here to view full article